Updates: Company News
Newcells Biotech collaborates with consortium in Eurostars funded project to advance novel therapy for Alpha-1 Antitrypsin (AAT) Deficiency
The Eurostars grant of €1.2m will support the partners, led by Gain, and includes Newcells, the Institute for Research in Biomedicine (Lausanne) and the University of Helsinki. Newcells will…
Read update
Newcells team support charity with festive jumpers
Thursday 8th December 2022 was Christmas Jumper Day in the UK to raise money for the charity Save the Children. A prize was given for the…
Read update
NB staff supports Motor Neurone Disease Charity
Having become engaged (now married!) in the summer of 2021, Will’s thoughts turned to arrangements for his stag party. Rather than take the traditional route Will hatched a plan…
Read update
Dr Kathryn Garner, Head of Kidney Development at NB
As she narrates her story, you have the impression that you have made the journey with her, her words becoming rich images in…
Read update
Thought Leadership Workshop hosted by NB: Emerging in vitro technologies for gene therapy applications
These include the first oligonucleotide-based therapies (Spinraza, Exondys, Vyondys), in vivo gene therapies (Luxturna and Zolgensma) and the first cell therapies (Kymriah, Yescarta, Tescartus). Such novel therapeutics treat disorders varying…
Read update
NB collaborates with Takeda Pharmaceuticals on renal drug safety evaluation study
Newcells Biotech and Takeda Pharmaceutical International Co. have collaborated in a study designed to assess drug safety. The study evaluated a set of 36 known drugs and…
Read update
